Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
6 studies found for:    elnd005

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
elnd005
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Enrolling by invitation A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Group 1 ELND005;   Drug: Group 2 ELND005
2 Completed A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Condition: Down Syndrome
Interventions: Drug: ELND005;   Drug: Placebo
3 Completed
Has Results 		ELND005 in Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Drug: Placebo Control;   Drug: ELND005
4 Completed ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: ELND005 (scyllo-inositol)
5 Recruiting Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: ELND005;   Drug: Placebo
6 Terminated Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
Condition: Bipolar 1 Disorder
Interventions: Drug: ELND005;   Drug: Lamotrigine;   Drug: Valproic acid;   Drug: Placebo
To Top

† Indicates status has not been verified in more than two years